Although no IBD-associated polymorphisms in RIPK2 have been identified as of yet, mutations in its activator XIAP have been linked to very early onset (VEO)-IBD in males through loss of XIAP ubiquitinating activity and subsequent inhibition of NOD/RIPK2 signaling [77,78,79]. This evidence concerns the gene RIPK2 and inflammatory bowel disease.